EMEA-001452-PIP01-13-M01

Key facts

Active substance
N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine (GSK1278863)
Therapeutic area
Uro-nephrology
Decision number
P/0025/2018
PIP number
EMEA-001452-PIP01-13-M01
Pharmaceutical form(s)
  • Oral solution
  • Oral suspension
  • Tablet
Condition(s) / indication(s)
Treatment of anaemia due to chronic disorders
Route(s) of administration
Oral use
Contact for public enquiries
GlaxoSmithKline R & D
Tel. +44 (0)20 8990 4242
E-mail: richard.x.braley@stiefel.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating